These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16608420)

  • 41. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
    Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
    Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
    Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
    Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular immunotherapies for prostate cancer.
    McNeel DG
    Biomed Pharmacother; 2007 Jul; 61(6):315-22. PubMed ID: 17306498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Quantitative changes of testosterone and prostate-specific antigen at low and high densities of PSA in men with prostate cancer].
    Khuskivadze AA; Kochiashvili DK
    Georgian Med News; 2007 Feb; (143):67-9. PubMed ID: 17404444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man--clinical trials at Memorial Sloan-Kettering Cancer Center.
    Slovin SF; Scher HI
    Semin Oncol; 1999 Aug; 26(4):448-54. PubMed ID: 10482187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic targeting: how to channel a minimal response for maximal outcome.
    Slovin SF
    Curr Opin Urol; 2006 May; 16(3):179-85. PubMed ID: 16679856
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Special report: vaccines for the treatment of prostate cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Apr; 24(6):1-2. PubMed ID: 20575182
    [No Abstract]   [Full Text] [Related]  

  • 49. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.
    Ozenci V; Miller AM; Palmborg A; Egevad L; Jaremko GA; Kälkner KM; Pisa P
    Prostate; 2005 Sep; 65(1):20-6. PubMed ID: 15800933
    [TBL] [Abstract][Full Text] [Related]  

  • 50. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1.
    Valenzuela HF; Pace KE; Cabrera PV; White R; Porvari K; Kaija H; Vihko P; Baum LG
    Cancer Res; 2007 Jul; 67(13):6155-62. PubMed ID: 17616672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer.
    Naruishi K; Timme TL; Kusaka N; Fujita T; Yang G; Goltsov A; Satoh T; Ji X; Tian W; Abdelfattah E; Men T; Watanabe M; Tabata K; Thompson TC
    Cancer Gene Ther; 2006 Jul; 13(7):658-63. PubMed ID: 16485011
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New molecular targets in advanced prostate cancer.
    Dawson NA
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer.
    Chiriva-Internati M; Yu Y; Mirandola L; D'Cunha N; Hardwicke F; Cannon MJ; Cobos E; Kast WM
    Prostate; 2012 Jan; 72(1):12-23. PubMed ID: 21520158
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
    Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK
    Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of PSA peptide mimotopes using phage display peptide library.
    Shanmugam A; Suriano R; Chaudhuri D; Rajoria S; George A; Mittelman A; Tiwari RK
    Peptides; 2011 Jun; 32(6):1097-102. PubMed ID: 21539876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
    Doehn C; Kausch I; Böhmer T; Sommerauer M; Jocham D
    Curr Opin Mol Ther; 2007 Apr; 9(2):183-9. PubMed ID: 17458173
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
    Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
    J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.